Liraglutide 3.0 mg

DRUG5 trials

Sponsors

University of Campinas, Brazil, Novo Nordisk A/S, The Cleveland Clinic

Conditions

Metabolism and Nutrition DisorderObesityOverweightType 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

CompletedNCT03856047

Novo Nordisk A/SObesity, Overweight

Start: 2019-03-01End: 2021-03-25Updated: 2024-07-05

Phase 3

Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

University of Campinas, BrazilObesity, Type 2 Diabetes Mellitus

Start: 2016-06-30End: 2017-04-30Target: 20Updated: 2016-03-24

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

CompletedNCT02963922

Novo Nordisk A/SMetabolism and Nutrition Disorder, Obesity

Start: 2017-02-06End: 2018-09-25Updated: 2020-03-30

Phase 4

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

TerminatedNCT04531176

The Cleveland ClinicObesity, Type 2 Diabetes

Start: 2020-09-01End: 2023-08-04Updated: 2024-09-19

Unknown Phase

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

CompletedNCT02773355

Novo Nordisk A/SObesity

Start: 2016-05-16End: 2022-02-28Updated: 2022-11-25

Related Papers

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

2021-11-16139 citations